Mayo Clinic\u2019de ara\u015ft\u0131rmac\u0131lar, y\u00fcksek riskli gliomlar\u0131n takibinde devrim niteli\u011finde bir y\u00f6ntem geli\u015ftirdi. Beyin t\u00fcm\u00f6rlerinin en agresif t\u00fcrlerinden biri olan y\u00fcksek dereceli gliomlar, h\u0131zl\u0131 ilerlemeleri ve olumsuz prognozlar\u0131yla uzun s\u00fcredir klinisyenlerin en b\u00fcy\u00fck zorluklar\u0131ndan biri olmu\u015ftur. Geleneksel tan\u0131 y\u00f6ntemleri yani MR g\u00f6r\u00fcnt\u00fcleme ve cerrahi biyopsiler, t\u00fcm\u00f6r\u00fcn ilerlemesini takip etme konusunda yetersiz ve riskli \u00e7\u00f6z\u00fcmler sunarken, Minnesota Rochester\u2019daki Mayo Clinic ara\u015ft\u0131rmac\u0131lar\u0131, hastaya \u00f6zel bir kan testiyle t\u00fcm\u00f6r dinamiklerini daha h\u0131zl\u0131, invaziv olmayan ve y\u00fcksek \u00f6zg\u00fcll\u00fckle takip etmenin m\u00fcmk\u00fcn oldu\u011funu g\u00f6sterdi.<\/p>\n
Y\u00fcksek dereceli gliomlar, yay\u0131lmac\u0131 do\u011fas\u0131 ve standart tedavilere direnciyle bilinen \u00f6l\u00fcmc\u00fcl beyin kanseri alt t\u00fcrlerinden biridir. Mevcut klinik uygulamalarda t\u00fcm\u00f6r ilerleyi\u015fini de\u011ferlendirmek i\u00e7in genellikle manyetik rezonans g\u00f6r\u00fcnt\u00fcleme (MRG) ve cerrahi biopsiler kullan\u0131lmaktad\u0131r. Ancak MRG \u00e7o\u011fu zaman t\u00fcm\u00f6r b\u00fcy\u00fcmesi ile tedaviye ba\u011fl\u0131 iltihap ya da skar dokusu aras\u0131nda net ayr\u0131m yapamaz. Bu da hastalar\u0131n tedavi planlamas\u0131nda gecikmelere yol a\u00e7ar. Cerrahi biyopsiler ise enfeksiyon ve n\u00f6rolojik hasar gibi yan riskleri i\u00e7ermesi nedeniyle tekrarlanabilir de\u011fildir ve hastalar i\u00e7in ek bir y\u00fck olu\u015fturur. \u0130\u015fte bu noktada geli\u015ftirilen ki\u015fiye \u00f6zel kan testi, dola\u015f\u0131mdaki t\u00fcm\u00f6r kaynakl\u0131 genetik materyali tespit ederek bu zorluklar\u0131n \u00fcstesinden gelmeyi vaat etmektedir.<\/p>\n
Bu y\u00f6ntemin kalbinde \u201cdola\u015f\u0131mdaki t\u00fcm\u00f6r DNA\u2019s\u0131\u201d (ctDNA) analizi yer almaktad\u0131r. Kanser h\u00fccrelerinin \u00f6l\u00fcm\u00fc sonucunda serbest kalan genetik materyalin kanda tespiti sonucu, t\u00fcm\u00f6r aktivitesi de\u011ferlendirilir. Ancak beyin t\u00fcm\u00f6rlerinde, kan-beyin bariyeri (KBB) adl\u0131 fizyolojik engel nedeniyle bu ctDNA\u2019n\u0131n kana ge\u00e7i\u015fi son derece k\u0131s\u0131tl\u0131d\u0131r. KBB, beyin mikro\u00e7evresinden molek\u00fcllerin d\u0131\u015far\u0131 \u00e7\u0131kmas\u0131n\u0131 engelledi\u011finden, beyin t\u00fcm\u00f6rlerinden kaynaklanan ctDNA\u2019n\u0131n kan dola\u015f\u0131m\u0131nda tespit edilmesi nadiren m\u00fcmk\u00fcn olur. Dolay\u0131s\u0131yla \u00f6nceki ctDNA tabanl\u0131 yakla\u015f\u0131mlar beyin t\u00fcm\u00f6rlerinde s\u0131n\u0131rl\u0131 ba\u015far\u0131 g\u00f6stermi\u015ftir.<\/p>\n
Mayo Clinic ara\u015ft\u0131rmac\u0131lar\u0131, KBB engelini a\u015fabilmek i\u00e7in t\u00fcm\u00f6re \u00f6zg\u00fc DNA birle\u015fim yerlerine odakland\u0131. T\u00fcm\u00f6r genomunda ger\u00e7ekle\u015fen kromozomal yeniden d\u00fczenlenmeler sonucu ortaya \u00e7\u0131kan bu benzersiz genetik k\u0131r\u0131lma noktalar\u0131, normal DNA dizilerinden farkl\u0131d\u0131r. \u00dcstelik bu birle\u015fim b\u00f6lgeleri genellikle \u00e7oklu kopya halinde amplifiye oldu\u011fundan, kanda tespit edilmeleri di\u011fer DNA par\u00e7alar\u0131na g\u00f6re \u00e7ok daha kolayd\u0131r. Hastaya \u00f6zel tasarlanan bu testler, bireysel t\u00fcm\u00f6r\u00fcn \u00f6zg\u00fcn DNA birle\u015fim noktalar\u0131n\u0131 hedefleyerek y\u00fcksek hassasiyetle t\u00fcm\u00f6rden kaynaklanan DNA\u2019y\u0131 ay\u0131rt edebilmektedir.<\/p>\n
Bu ki\u015fiselle\u015ftirilmi\u015f testlerin geli\u015ftirilmesi a\u015famas\u0131nda, \u00f6ncelikle her hastan\u0131n t\u00fcm\u00f6r dokusundan t\u00fcm genom dizilemesi yap\u0131ld\u0131. B\u00f6ylece, karma\u015f\u0131k genetik yap\u0131ya sahip t\u00fcm\u00f6rlerdeki yeniden d\u00fczenlenmi\u015f DNA birle\u015fim noktalar\u0131 haritaland\u0131. Ortaya \u00e7\u0131kan detayl\u0131 molek\u00fcler profil sayesinde, her hastaya \u00f6zg\u00fc tan\u0131sal testler haz\u0131rland\u0131. Bu yakla\u015f\u0131m, kanser y\u00f6netiminde bireye \u00f6zel tedaviler sa\u011flamaya y\u00f6nelik g\u00fcncel ki\u015fiselle\u015ftirilmi\u015f t\u0131p anlay\u0131\u015f\u0131 ile uyumludur. Testin \u00f6zg\u00fcll\u00fc\u011f\u00fc sayesinde, dola\u015f\u0131mdaki normal DNA par\u00e7alar\u0131yla kar\u0131\u015f\u0131kl\u0131k ya\u015fanmadan sadece t\u00fcm\u00f6r DNA\u2019s\u0131 takip edilebilmektedir.<\/p>\n
Ara\u015ft\u0131rma kapsam\u0131nda bu ki\u015fiye \u00f6zel testlerin ba\u015far\u0131s\u0131 dikkat \u00e7ekicidir. Test uygulanan vakalarda, hedef DNA birle\u015fim noktalar\u0131n\u0131n bulundu\u011fu durumlarda t\u00fcm\u00f6r DNA\u2019s\u0131 yakla\u015f\u0131k %93 oran\u0131nda ba\u015far\u0131yla tespit edildi. Bu, zorlu biyolojik ko\u015fullara ra\u011fmen olduk\u00e7a y\u00fcksek bir oran olarak kabul edilmektedir. Daha da \u00f6nemlisi, baz\u0131 hastalarda kan plazmas\u0131ndaki t\u00fcm\u00f6r DNA seviyeleri, radyolojik g\u00f6r\u00fcnt\u00fclerde t\u00fcm\u00f6r ilerlemesi ortaya \u00e7\u0131kmadan \u00f6nce y\u00fckselmeye ba\u015flam\u0131\u015ft\u0131r. Bu zaman avantaj\u0131, klinisyenlere hastal\u0131\u011f\u0131n gidi\u015fat\u0131n\u0131 erken d\u00f6nemde yakalama ve tedavi stratejilerini \u00f6nceden de\u011fi\u015ftirme olana\u011f\u0131 sunmaktad\u0131r.<\/p>\n
Bu yenilik\u00e7i teknoloji sadece ilerlemenin do\u011frulanmas\u0131 i\u00e7in de\u011fil, t\u00fcm\u00f6r b\u00fcy\u00fcmesini destekleyen molek\u00fcler mekanizmalar\u0131n da izlenmesi i\u00e7in yeni bilgiler sa\u011flamaktad\u0131r. Dola\u015f\u0131mdaki amplifiye DNA birle\u015fim noktalar\u0131n\u0131n varl\u0131\u011f\u0131 ve miktar\u0131, t\u00fcm\u00f6r\u00fcn genetik evrimini ger\u00e7ek zamanl\u0131 olarak yans\u0131tabilir. B\u00f6ylece onkologlar, gliomlar\u0131n tedaviye yan\u0131t\u0131n\u0131 veya ila\u00e7lara kar\u015f\u0131 geli\u015ftirdikleri diren\u00e7 mekanizmalar\u0131n\u0131 molek\u00fcler d\u00fczeyde takip edebilecektir. Bu dinamik takip, periyodik g\u00f6r\u00fcnt\u00fclemeye dayal\u0131 statik y\u00f6ntemlerin \u00f6tesinde, ki\u015fiye \u00f6zel m\u00fcdahalelerin \u015fekillenmesine zemin haz\u0131rlayabilir.<\/p>\n
Molek\u00fcler genetik\u00e7iler ile beyin cerrahlar\u0131 aras\u0131nda ger\u00e7ekle\u015fen i\u015fbirli\u011fi, bu ara\u015ft\u0131rmay\u0131 m\u00fcmk\u00fcn k\u0131lm\u0131\u015ft\u0131r. Biomarker ke\u015ffi alan\u0131nda \u00f6nc\u00fc isimlerden Dr. George Vasmatzis, gliomlar\u0131n genetik yeniden d\u00fczenlenmelerinin anla\u015f\u0131lmas\u0131n\u0131n yeni tedavi se\u00e7eneklerini ortaya \u00e7\u0131karma a\u00e7\u0131s\u0131ndan kritik oldu\u011funu belirtmektedir. N\u00f6ro\u015fir\u00fcrji uzman\u0131 Dr. Terry Burns ise, radyolojik ilerleme tamamland\u0131ktan sonra ba\u015flayan reaktif tedavilerden, kan\u0131n molek\u00fcler imzalar\u0131 sayesinde ilerlemeyi \u00f6nceden tespit eden ve bu do\u011frultuda proaktif kararlar alan yeni bir paradigma ihtiyac\u0131n\u0131 vurgulamaktad\u0131r.<\/p>\n
Gelecekte ara\u015ft\u0131rmac\u0131lar, bu bulgular\u0131 daha geni\u015f hasta gruplar\u0131nda do\u011frulamay\u0131 planlamaktad\u0131r. Klinik sonu\u00e7lar ve g\u00f6r\u00fcnt\u00fcleme bulgular\u0131 ile kan tabanl\u0131 izleme aras\u0131ndaki uyumun de\u011ferlendirilmesi, testin klinik kullan\u0131ma girmesi ad\u0131na kritik \u00f6nemdedir. Ayr\u0131ca platformun esnek yap\u0131s\u0131, di\u011fer beyin t\u00fcm\u00f6rleri ya da genetik bozukluklar\u0131n temelinde yatan n\u00f6rolojik hastal\u0131klar i\u00e7in de uyarlanabilir. B\u00f6ylece bu teknolojinin etki alan\u0131 gliomlar\u0131n \u00f6tesine ge\u00e7ebilir.<\/p>\n
Her ne kadar ara\u015ft\u0131rma hen\u00fcz erken safhalarda olsa da, bu geli\u015fme beyin t\u00fcm\u00f6rlerinin invaziv olmayan, daha hassas ve daha s\u0131k izlenebilmesi i\u00e7in \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131d\u0131r. Kan-beyin bariyerinin ve gliomlar\u0131n heterojen yap\u0131s\u0131n\u0131n yaratt\u0131\u011f\u0131 engeller, genomik teknolojiler ile klinik deneyimin birle\u015fmesiyle a\u015f\u0131lmaya ba\u015flam\u0131\u015ft\u0131r. Bu test, agresif beyin kanserlerinde daha erken m\u00fcdahalelere olanak tan\u0131yarak hastalar i\u00e7in umut \u0131\u015f\u0131\u011f\u0131 do\u011furabilir.<\/p>\n
Onkolojinin giderek ki\u015fiselle\u015fen d\u00fcnyas\u0131nda, bu t\u00fcr y\u00f6ntemler standart bak\u0131m uygulamalar\u0131n\u0131 yeniden \u015fekillendirebilir. Kabaca sadece t\u00fcm\u00f6r de\u011fi\u015fimlerinin kesintili g\u00f6r\u00fcnt\u00fcleme g\u00f6r\u00fcnt\u00fcleriyle verilmesi yerine, s\u00fcrekli molek\u00fcler izleme ile dinamik adaptif tedavilerin geli\u015ftirilmesi m\u00fcmk\u00fcn hale gelecektir. Bu \u00e7al\u0131\u015fma, genomik, molek\u00fcler biyoloji ve klinik uzmanl\u0131\u011f\u0131n birle\u015fmesiyle yenilik\u00e7i kanser tan\u0131s\u0131 alan\u0131nda yeni ufuklar a\u00e7maktad\u0131r.<\/p>\n
T\u00fcm detaylar\u0131 ile ara\u015ft\u0131rman\u0131n sonu\u00e7lar\u0131 \u2018Clinical Cancer Research\u2019 adl\u0131 sayg\u0131n uluslararas\u0131 dergide yay\u0131mlanm\u0131\u015f olup, metodolojinin ve verilerin bilimsel dayanaklar\u0131n\u0131 kapsaml\u0131 \u015fekilde sunmaktad\u0131r. Hem onkologlar hem ara\u015ft\u0131rmac\u0131lar hem de hastalar i\u00e7in y\u00fcksek-grade gliomlarla m\u00fccadelenin yeni yollar\u0131n\u0131 g\u00f6stererek, ki\u015fiselle\u015ftirilmi\u015f bilimle kanser bak\u0131m\u0131nda s\u0131n\u0131rlar\u0131n nas\u0131l zorlanabilece\u011fini ortaya koymaktad\u0131r.<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Personalized monitoring of high-grade gliomas using tumor-specific amplified DNA junctions circulating in peripheral blood.<\/p>\n Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Personalized Tumor-Specific Amplified DNA Junctions in Peripheral Blood of Patients with High-Grade Gliomas<\/p>\n Haberin Yay\u0131n Tarihi<\/strong>: 28-Mar-2025<\/p>\n Web References<\/strong>: Anahtar Kelimeler<\/strong>: Mayo Clinic\u2019de ara\u015ft\u0131rmac\u0131lar, y\u00fcksek riskli gliomlar\u0131n takibinde devrim niteli\u011finde bir y\u00f6ntem geli\u015ftirdi. Beyin t\u00fcm\u00f6rlerinin en agresif t\u00fcrlerinden biri olan y\u00fcksek dereceli gliomlar, h\u0131zl\u0131 ilerlemeleri ve olumsuz prognozlar\u0131yla uzun s\u00fcredir klinisyenlerin en b\u00fcy\u00fck zorluklar\u0131ndan biri olmu\u015ftur. Geleneksel tan\u0131 y\u00f6ntemleri yani MR g\u00f6r\u00fcnt\u00fcleme ve cerrahi biyopsiler, t\u00fcm\u00f6r\u00fcn ilerlemesini takip etme konusunda yetersiz ve riskli \u00e7\u00f6z\u00fcmler sunarken, Minnesota…<\/p>\n","protected":false},"author":1,"featured_media":3801,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[3033,3032,3029,3031,3030],"tmauthors":[],"class_list":{"0":"post-3800","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-gliom-tedavisinde-invaziv-olmayan-takip-yontemleri","9":"tag-kan-beyin-bariyeri-asan-genetik-biyobelirtecler","10":"tag-kisisellestirilmis-beyin-kanseri-takip-yontemi","11":"tag-mayo-clinic-beyin-tumoru-kan-testi","12":"tag-yuksek-dereceli-gliomlarda-ctdna-analizi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Mayo-Klinik8217ten-Kisisellestirilmis-Beyin-Kanseri-Takip-Yontemi-1745515777.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3800"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3800\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3801"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3800"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n– Clinical Cancer Research Article
\n– Mayo Clinic
\n– Gliomas Information
\n– Brain Tumor Information<\/p>\n
\nGliomas, High-grade glioma, Brain cancer, Circulating tumor DNA, DNA junctions, Blood-brain barrier, Personalized medicine, Biomarker discovery, Whole genome sequencing, Molecular diagnostics, Tumor monitoring, Peripheral blood assay<\/p>\n","protected":false},"excerpt":{"rendered":"